CD8A and neoplasm: Deletion or blockade of PSGL-1 allows CD8+ T cells to gain enhanced TCR sensitivity and metabolic characteristics, promoting their effector function and stem cell differentiation, and achieving successful tumor control in solid tumors resistant to PD-1 blockade [225].